Citius Pharmaceuticals (CTXR) Earnings Date, Estimates & Call Transcripts $1.85 -0.30 (-13.95%) Closing price 02/20/2025 04:00 PM EasternExtended Trading$1.86 +0.01 (+0.81%) As of 02/20/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Citius Pharmaceuticals Latest Earnings SummaryLatest Q1 2025 Earnings DateFeb. 14EstimatedActual EPS (Feb. 14) -$1.30 Missed By -$0.05 Consensus EPS (Feb. 14) -$1.25 Citius Pharmaceuticals issued Q1 2025 earnings on February 14, 2025, reporting an EPS of -$1.30, which missed analysts' consensus estimates of -$1.25 by $0.05. With a trailing EPS of $0.00, Citius Pharmaceuticals' earnings are expected to grow next year, from ($4.50) to $1.25 per share. Get Citius Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataCTXR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.CTXR Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Citius Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.05-$0.05-$0.05Q2 20251-$0.05-$0.05-$0.05Q3 20251-$0.04-$0.04-$0.04Q4 20251-$0.04-$0.04-$0.04FY 20254($0.18)($0.18)($0.18) Citius Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails2/14/2025Q1 2025-$1.25-$1.30 -$0.05-$1.30--8/12/2024--$1.25-$1.50 -$0.25-$0.06--5/14/2024Q2 2024-$1.50-$1.25+$0.25-$0.05--2/14/2024Q1 2024$3.25-$1.50 -$4.75-$0.06--12/29/2023Q4 2023-$0.50-$1.75 -$1.25-$0.07--8/14/2023Q3 2023-$1.50-$1.50--$0.06--5/12/2023Q2 2023-$1.00-$1.75 -$0.75-$0.07-- Citius Pharmaceuticals Earnings - Frequently Asked Questions When did Citius Pharmaceuticals announce their last quarterly earnings? Citius Pharmaceuticals (NASDAQ:CTXR) last announced its quarterly earning data on Friday, February 14, 2025. Learn more on CTXR's earnings history. Did Citius Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Citius Pharmaceuticals (NASDAQ:CTXR) missed the analysts' consensus estimate of ($1.25) by $0.05 with a reported earnings per share (EPS) of ($1.30). Learn more on analysts' earnings estimate vs. CTXR's actual earnings. How much profit does Citius Pharmaceuticals generate each year? Citius Pharmaceuticals (NASDAQ:CTXR) has a recorded net income of -$39.14 million. CTXR has generated $0.00 earnings per share over the last four quarters. What is Citius Pharmaceuticals's EPS forecast for next year? Citius Pharmaceuticals's earnings are expected to grow from ($4.50) per share to $1.25 per share in the next year. More Earnings Resources from MarketBeat Related Companies Jasper Therapeutics Earnings Alto Neuroscience Earnings Skye Bioscience Earnings DBV Technologies Earnings Immunic Earnings Citius Oncology Earnings Galectin Therapeutics Earnings Inozyme Pharma Earnings Acumen Pharmaceuticals Earnings Entera Bio Earnings Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? This page (NASDAQ:CTXR) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
